PLYMOUTH MEETING, Pa.,
Aug. 1, 2014 /PRNewswire/ -- Inovio
Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that it will
host a conference call to report its second quarter 2014 financial
results on Monday, August 11, 2014 at
9:00 AM ET. CEO Dr. J. Joseph Kim and CFO Peter Kies will discuss second quarter earnings,
provide a corporate update, and participate in a live Q&A with
analysts. The update will include clinical development plans for
VGX-3100, Inovio's immune therapy targeting pre-cancers and cancers
associated with HPV.
The audio presentation will be broadcast online at
http://www.investorcalendar.com/IC/CEPage.asp?ID=173061. Investors
can also access the presentation through the "Webcast" tab on
Inovio's home page at www.inovio.com. This is a listen-only
event.
A replay of the conference call will be available beginning two
hours after the call until Sep. 11,
2014. To access the replay by telephone, dial 877-660-6853
(domestic) or 201-612-7415 (international) and use passcode
13588210. The replay will also be available as a webcast until
November 11, 2014 and can be found
under the "Webcast" tab on Inovio's website.
About Inovio Pharmaceuticals, Inc.
Inovio is revolutionizing the fight against cancer and
infectious diseases. Our immunotherapies uniquely activate
best-in-class immune responses to prevent and treat disease, and
have shown clinically significant efficacy with a favorable safety
profile. With an expanding portfolio of immune therapies, the
company is advancing a growing preclinical and clinical stage
product pipeline. Partners and collaborators include Roche,
University of Pennsylvania, NIH, HIV
Vaccines Trial Network, National Cancer Institute, U.S.
Military HIV Research Program, and University of
Manitoba. For more information, visit www.inovio.com.
This press release contains certain forward-looking
statements relating to our business, including our plans to develop
electroporation-based drug and gene delivery technologies and DNA
vaccines and our capital resources. Actual events or results may
differ from the expectations set forth herein as a result of a
number of factors, including uncertainties inherent in pre-clinical
studies, clinical trials and product development programs
(including, but not limited to, the fact that pre-clinical and
clinical results referenced in this release may not be indicative
of results achievable in other trials or for other indications,
that the studies or trials may not be successful or achieve the
results desired, including safety and efficacy for VGX-3100, that
pre-clinical studies and clinical trials may not commence or be
completed in the time periods anticipated, that results from one
study may not necessarily be reflected or supported by the results
of other similar studies and that results from an animal study may
not be indicative of results achievable in human studies), the
availability of funding to support continuing research and studies
in an effort to prove safety and efficacy of electroporation
technology as a delivery mechanism or develop viable DNA vaccines,
our ability to support our broad pipeline of SynCon®
active immune therapy and vaccine products, the adequacy of our
capital resources, the availability or potential availability of
alternative therapies or treatments for the conditions targeted by
the company or its collaborators, including alternatives that may
be more efficacious or cost-effective than any therapy or treatment
that the company and its collaborators hope to develop, evaluation
of potential opportunities, issues involving product liability,
issues involving patents and whether they or licenses to them will
provide the company with meaningful protection from others using
the covered technologies, whether such proprietary rights are
enforceable or defensible or infringe or allegedly infringe on
rights of others or can withstand claims of invalidity and whether
the company can finance or devote other significant resources that
may be necessary to prosecute, protect or defend them, the level of
corporate expenditures, assessments of the company's technology by
potential corporate or other partners or collaborators, capital
market conditions, the impact of government healthcare proposals
and other factors set forth in our Annual Report on Form 10-K
for the year ended December 31, 2013, our Form 10-Q for the
quarter ended March 31, 2014, and
other regulatory filings from time to time. There can be no
assurance that any product in Inovio's pipeline will be
successfully developed or manufactured, that final results of
clinical studies will be supportive of regulatory approvals
required to market licensed products, or that any of the
forward-looking information provided herein will be proven
accurate.
CONTACTS:
|
|
Investors:
|
Bernie Hertel, Inovio
Pharmaceuticals, 858-410-3101, bhertel@inovio.com
|
Media:
|
Jeff Richardson,
Inovio Pharmaceuticals, 267-440-4211,
jrichardson@inovio.com
|
Logo -
http://photos.prnewswire.com/prnh/20131118/LA18202LOGO
SOURCE Inovio Pharmaceuticals, Inc.